STAAR Surgical Increases Sales but Misses Revenue Estimate
STAAR Surgical (NAS: STAA) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 30 (Q1), STAAR Surgical missed estimates on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share was unchanged.
Gross margin and operating margin grew, while net margins contracted.
STAAR Surgical notched revenue of $15.5 million. The five analysts polled by S&P Capital IQ expected net sales of $16.9 million on the same basis. GAAP-reported sales were 4.4% higher than the prior-year quarter's $14.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.04. The three earnings estimates compiled by S&P Capital IQ predicted $0.03 per share. GAAP EPS of $0.01 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 70.3%, 550 basis points better than the prior-year quarter. Operating margin was 1.8%, 40 basis points better than the prior-year quarter. Net margin was 1.5%, 50 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $18.5 million. On the bottom line, the average EPS estimate is $0.04.
Next year's average estimate for revenue is $72.8 million. The average EPS estimate is $0.13.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 93 members rating the stock outperform and 13 members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give STAAR Surgical a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is buy, with an average price target of $12.60.
The health-care investing landscape is littered with also-rans and a few major winners. Is STAAR Surgical performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add STAAR Surgical to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.